Rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis (Registro nro. 22724)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03107nam a2200361 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260804123817.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Torkildsen, Øivind |
| Rol del Autor | Autor |
| 9 (RLIN) | 53663 |
| 245 ## - Titulo | |
| Titulo | Rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis |
| 300 ## - Páginas | |
| Paginación | páginas: 32-43 |
| 520 ## - Resumen | |
| Resumen | Background: Anti-CD20 monoclonal antibodies are effective for relapsing multiple sclerosis. However, data from head-to-head trials are lacking.<br/>Methods: In this phase 3, multicenter, double-blind, noninferiority trial, we randomly assigned adults with newly diagnosed relapsing multiple sclerosis and recent disease activity in a 3:2 ratio to receive rituximab or ocrelizumab every 6 months for 24 months. The primary end point was the absence of new or enlarging lesions on T2-weighted magnetic resonance imaging (MRI) from month 6 to month 24. Noninferiority was defined as a lower limit of the 95% confidence interval for the risk difference (rituximab minus ocrelizumab) of greater than or equal to −10 percentage points. Secondary end points included efficacy and safety.<br/>Results: A total of 218 participants underwent randomization; 216 received treatment (132 assigned to the rituximab group and 84 assigned to the ocrelizumab group). Between months 6 and 24, the estimated probability of having no new or enlarging lesions detected on T2-weighted MRI was 92.2% with rituximab and 94.8% with ocrelizumab, corresponding to a risk difference of –2.6 percentage points (95% confidence interval, –9.4 to 4.3), which met the prespecified noninferiority criterion. Relapse rates, disability outcomes, and cognitive-performance profiles appeared to be similar in the two groups. Infections were more common in the rituximab group than in the ocrelizumab group (in 82% vs. 69% of participants), although the percentage of participants with serious adverse events was similar in the two groups (8% and 7%, respectively).<br/>Conclusions: In participants with newly diagnosed relapsing multiple sclerosis and recent disease activity, rituximab was noninferior to ocrelizumab in suppressing disease activity as detected by MRI from 6 to 24 months, with a similar incidence of serious adverse events. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ALERGIA |
| 9 (RLIN) | 7055 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | INMUNOLOGÍA GENERAL |
| 9 (RLIN) | 53664 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENFERMEDAD AUTOINMUNE |
| 9 (RLIN) | 53665 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | MEDICINA CLINICA GENERAL |
| 9 (RLIN) | 53666 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENFERMEDAD INFLAMATORIA |
| 9 (RLIN) | 53667 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ESCLEROSIS MULTIPLE |
| 9 (RLIN) | 14091 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | NEUROLOGÍA |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | NEUROCIRUGÍA GENERAL |
| 9 (RLIN) | 53668 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | OFTALMOLOGÍA |
| 9 (RLIN) | 32364 |
| 700 ## - Autor Personal | |
| Autor Personal | Kjelgaard Brustad, Hilde |
| 9 (RLIN) | 53669 |
| 700 ## - Autor Personal | |
| Autor Personal | Høgestøl, Einar August |
| 9 (RLIN) | 53670 |
| 700 ## - Autor Personal | |
| Autor Personal | Alstadhaug, Karl Bjørnar |
| 9 (RLIN) | 53671 |
| 700 ## - Autor Personal | |
| Autor Personal | Bhan, Alok |
| 9 (RLIN) | 53672 |
| 700 ## - Autor Personal | |
| Autor Personal | Flemmen, Heidi Øyen |
| 9 (RLIN) | 53673 |
| 700 ## - Autor Personal | |
| Autor Personal | Habbestad, Andrea |
| 9 (RLIN) | 53674 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22634 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM001 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-07-31 |
| Catalogador | sqb |
No hay ítems disponibles.